No more tears from surgical site infections in interventional pain management

키워드

참고문헌 (151)

1. Berríos-Torres SI, "Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017", JAMA Surg, 152, pp.784~791 (2017)
2. "of surgical site infections and prevention indicators in European hospitals. HAI-Net SSI protocol, version 2.2" (2017)[URL]
3. Skube SJ, "Characterizing surgical site infection signals in clinical notes", Stud Health Technol Inform, 245, pp.955~959 (2017)
4. "Global guidelines for the prevention of surgical site infection, second edition" (2018)[URL]
5. Sepkowitz KA, "One hundred years of Salvarsan", N Engl J Med, 365, pp.291~293 (2011)
6. Williams KJ, "The introduction of 'chemotherapy'using arsphenamine-the first magic bullet", J R Soc Med, 102, pp.343~348 (2009)
7. Aminov RI, "A brief history of the antibiotic era : lessons learned and challenges for the future", Front Microbiol, 1, pp.134~ (2010)
8. Hutchings MI, "Antibiotics : past, present and future", Curr Opin Microbiol, 51, pp.72~80 (2019)
9. Singh SB, "What is an"ideal"antibiotic? Discovery challenges and path forward", Biochem Pharmacol, 133, pp.63~73 (2017)
10. Kapoor G, "Action and resistance mechanisms of antibiotics : a guide for clinicians", J Anaesthesiol Clin Pharmacol, 33, pp.300~305 (2017)
11. Tsantes AG, "Spinal infections : an update", Microorganisms, 8, pp.476~ (2020)
12. Buckman SA, "Empiric antibiotics for sepsis", Surg Infect(Larchmt), 19, pp.147~154 (2018)
13. Ahmed A, "Current concepts in combination antibiotic therapy for critically ill patients", Indian J Crit Care Med, 18, pp.310~314 (2014)
14. Bassetti M, "New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections", Curr Opin Crit Care, 21, pp.402~411 (2015)
15. Schmid A, "Monotherapy versus combination therapy for multidrug-resistant Gramnegative infections : systematic review and metaanalysis", Sci Rep, 9, pp.15290~ (2019)
16. Shaffer WO, "An evidence-based clinical guideline for antibiotic prophylaxis in spine surgery", Spine J, 13, pp.1387~1392 (2013)
17. Follett KA, "Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections", Anesthesiology, 100, pp.1582~1594 (2004)
18. Ierano C, "Surgical antimicrobial prophylaxis", Aust Prescr, 40, pp.225~229 (2017)
19. Shawky Abdelgawaad A, "Perioperative antibiotic prophylaxis in spinal surgery", SICOT J, 7, pp.31~ (2021)
20. Alexander JW, "Updated recommendations for control of surgical site infections", Ann Surg, 253, pp.1082~1093 (2011)
21. Schaison G, "Teicoplanin in the treatment of serious infection", J Chemother, 12(Suppl 5), pp.26~33 (2000)
22. Schwartz RH, "Successful reimplantation of spinal cord stimulator one year after device removal due to infection", Surg J(N Y), 7, pp.e11~e13 (2021)
23. Deer TR, "The Neurostimulation Appropriateness Consensus Committee (NACC) recommendations for infection prevention and management", Neuromodulation, 20, pp.31~50 (2017)
24. Mok JM, "Use of C-reactive protein after spinal surgery : comparison with erythrocyte sedimentation rate as predictor of early postoperative infectious complications", Spine(Phila Pa 1976), 33, pp.415~421 (2008)
25. Pepys MB, "C-reactive protein: a critical update", J Clin Invest, 112, pp.1805~1812 (2003)
26. Black S, "C-reactive protein", J Biol Chem, 279, pp.48487~48490 (2004)
27. Du Clos TW, "Function of C-reactive protein", Ann Med, 32, pp.274~278 (2000)
28. Hoeller S, "C-reactive protein in spinal surgery : more predictive than prehistoric", Eur Spine J, 30, pp.1261~1269 (2021)
29. Bray C, "Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine", WMJ, 115, pp.317~321 (2016)
30. Zheng S, "Usefulness of inflammatory markers and clinical manifestation for an earlier method to diagnosis surgical site infection after spinal surgery", Int Orthop, 44, pp.2211~2219 (2020)
31. Jönsson B, "Erythrocyte sedimentation rate after lumbar spine surgery", Spine(Phila Pa 1976), 16, pp.1049~1050 (1991)
32. Akram Zare, "Spinal Surgery and Subsequent ESR and WBC Changes Pattern: A Single Center Prospective Study", Korean Journal of Neurotrauma, 17(2), pp.136~147 (2021), 대한신경손상학회[DOI]
33. Takahashi J, "Usefulness of white blood cell differential for early diagnosis of surgical wound infection following spinal instrumentation surgery", Spine(Phila Pa 1976), 31, pp.1020~1025 (2006)
34. Kraft CN, "CRP and leukocyte-count after lumbar spine surgery : fusion vs. nucleotomy", Acta Orthop, 82, pp.489~493 (2011)
35. Man Kyu Choi, "Sequential Changes of Plasma C-Reactive Protein, Erythrocyte Sedimentation Rate and White Blood Cell Count in Spine Surgery : Comparison between Lumbar Open Discectomy and Posterior Lumbar Interbody Fusion", 대한신경외과학회지, 56(3), pp.218~223 (2014), 대한신경외과학회[DOI]
36. Aljabi Y, "Value of procalcitonin as a marker of surgical site infection following spinal surgery", Surgeon, 17, pp.97~101 (2019)
37. Nie H, "Procalcitonin as an early predictor of postoperative infectious complications in patients with acute traumatic spinal cord injury", Spinal Cord, 49, pp.715~720 (2011)
38. Deguchi M, "The usefulness of serum amyloid A as a postoperative inflammatory marker after posterior lumbar interbody fusion", J Bone Joint Surg Br, 92, pp.555~559 (2010)
39. Sack GH Jr, "Serum amyloid A-a review", Mol Med, 24, pp.46~ (2018)
40. Chahoud J, "Surgical site infections following spine surgery : eliminating the controversies in the diagnosis", Front Med(Lausanne), 1, pp.7~ (2014)
41. Amanai E, "Usefulness of presepsin for the early detection of infectious complications after elective colorectal surgery, compared with Creactive protein and procalcitonin", Sci Rep, 12, pp.3960~ (2022)
42. Lee S, "Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock : a prospective observational study according to the Sepsis-3 definitions", BMC Infect Dis, 22, pp.8~ (2022)
43. Giavarina D, "Determination of reference interval for presepsin, an early marker for sepsis", Biochem Med (Zagreb), 25, pp.64~68 (2015)
44. Zhu X, "Usage of procalcitonin and sCD14-ST as diagnostic markers for postoperative spinal infection", J Orthop Traumatol, 23, pp.25~ (2022)
45. Koakutsu T, "Postoperative changes in presepsin level and values predictive of surgical site infection after spinal surgery: a single-center, prospective observational study", Spine (Phila Pa 1976), 43, pp.578~584 (2018)
46. Zou Q, "Presepsin as a novel sepsis biomarker", World J Emerg Med, 5, pp.16~19 (2014)
47. Cheng MP, "Blood culture results before and after antimicrobial administration in patients with severe manifestations of sepsis : a diagnostic study", Ann Intern Med, 171, pp.547~554 (2019)
48. Opota O, "Blood culture-based diagnosis of bacteraemia : state of the art", Clin Microbiol Infect, 21, pp.313~322 (2015)
49. Khan ZA, "Current and emerging methods of antibiotic susceptibility testing", Diagnostics (Basel), 9, pp.49~ (2019)
50. "How antimicrobial resistance happens" (2020)[URL]
51. Jorgensen JH, "Antimicrobial susceptibility testing : a review of general principles and contemporary practices", Clin Infect Dis, 49, pp.1749~1755 (2009)
52. "M100: performance standards for antimicrobial susceptibility testing" (2022)[URL]
53. "Rationale documents from EUCAST" (2022)[URL]
54. Humphries RM, "Understanding and addressing CLSI breakpoint revisions : a primer for clinical laboratories", J Clin Microbiol, 57, pp.e00203~e00219 (2019)
55. Brown D, "Harmonization of antimicrobial susceptibility testing breakpoints in Europe : implications for reporting intermediate susceptibility", J Antimicrob Chemother, 65, pp.183~185 (2010)
56. "Updating breakpoints in antimicrobial susceptibility testing" (2022)[URL]
57. Andrews JM, "Determination of minimum inhibitory concentrations", J Antimicrob Chemother, 48(Suppl 1), pp.5~16 (2001)
58. Saito A, "Clinical breakpoints in pulmonary infections and sepsis : new antimicrobial agents and supplemental information for some agents already released", J Infect Chemother, 5, pp.223~226 (1999)
59. "MIC and time- vs. concentration-dependent killing" (2021)[URL]
60. 최은지, "Unexpected extrusion of the implantable pulse generator of the spinal cord stimulator - A case report -", Anesthesia and Pain Medicine, 16(1), pp.103~107 (2021), 대한마취통증의학회[DOI]
61. Yazdi C, "Management of intrathecal pump site infection in a patient with metastatic breast cancer without the removal of the system, a case report", J Anesth Intensive Care Med, 1, pp.555568~ (2017)
62. Falowski SM, "Spinal cord stimulation infection rate and risk factors : results from a United States payer database", Neuromodulation, 22, pp.179~189 (2019)
63. Bendel MA, "Spinal cord stimulator related infections : findings from a multicenter retrospective analysis of 2737 implants", Neuromodulation, 20, pp.553~557 (2017)
64. Hoelzer BC, "Spinal cord stimulator implant infection rates and risk factors : a multicenter retrospective study", Neuromodulation, 20, pp.558~562 (2017)
65. Loubet P, "Cefazolin versus anti-staphylococcal penicillins for treatment of methicillinsusceptible Staphylococcus aureus bacteraemia : a narrative review", Clin Microbiol Infect, 24, pp.125~132 (2018)
66. Brook I, "Inoculum effect", Rev Infect Dis, 11, pp.361~368 (1989)
67. Miller WR, "The cefazolin inoculum effect is associated with increased mortality in methicillinsusceptible Staphylococcus aureus bacteremia", Open Forum Infect Dis, 5 (2018)
68. Lenhard JR, "Inoculum effect of β-lactam antibiotics", J Antimicrob Chemother, 74, pp.2825~2843 (2019)
69. Carmona-Fontaine C, "Altruistic cell death and collective drug resistance", Mol Syst Biol, 8, pp.627~ (2012)
70. Bamberger DM, "Management of Staphylococcus aureus infections", Am Fam Physician, 72, pp.2474~2481 (2005)
71. Warner NS, "Peripheral nerve stimulation and clinical outcomes : a retrospective case series", Pain Pract, 21, pp.411~418 (2021)
72. Ilfeld BM, "Infection rates of electrical leads used for percutaneous neurostimulation of the peripheral nervous system", Pain Pract, 17, pp.753~762 (2017)
73. Delhaas EM, "Complications associated with intrathecal drug delivery systems", BJA Educ, 20, pp.51~57 (2020)
74. Malheiro L, "Infectious complications of intrathecal drug administration systems for spasticity and chronic pain : 145 patients from a tertiary care center", Neuromodulation, 18, pp.421~427 (2015)
75. Ruppen W, "Infection rates associated with epidural indwelling catheters for seven days or longer : systematic review and meta-analysis", BMC Palliat Care, 6, pp.3~ (2007)
76. Harde M, "A comparative study of epidural catheter colonization and infection in Intensive Care Unit and wards in a Tertiary Care Public Hospital", Indian J Crit Care Med, 20, pp.109~113 (2016)
77. Brown MM, "Staphylococcus epidermidis-skin friend or foe?", PLoS Pathog, 16, pp.e1009026~ (2020)
78. Cau L, "Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis", J Allergy Clin Immunol, 147, pp.955~966 (2021)
79. Otto M, "Staphylococcus epidermidis--the 'accidental'pathogen", Nat Rev Microbiol, 7, pp.555~567 (2009)
80. Kumar G, "Milwaukee Initiative in Critical Care Outcomes Research (MICCOR) Group of Investigators. Nationwide trends of severe sepsis in the 21st century (2000-2007)", Chest, 140, pp.1223~1231 (2011)
81. de Jong PC, "A comparison of epidural catheters with or without subcutaneous injection ports for treatment of cancer pain", Anesth Analg, 78, pp.94~100 (1994)
82. 심지수, "Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports", Korean Journal of Radiology, 15(4), pp.494~500 (2014), 대한영상의학회[DOI]
83. 김경훈, "All about pain pharmacology: what pain physicians should know", The Korean Journal of Pain, 33(2), pp.108~120 (2020), 대한통증학회[DOI]
84. Park JW, "Infection following percutaneous vertebral augmentation with polymethylmethacrylate", Arch Osteoporos, 13, pp.47~ (2018)
85. Abdelrahman H, "Infection after vertebroplasty or kyphoplasty. A series of nine cases and review of literature", Spine J, 13, pp.1809~1817 (2013)
86. Hernandez L, "New injectable and radiopaque antibiotic loaded acrylic bone cements", J Biomed Mater Res B Appl Biomater, 87, pp.312~320 (2008)
87. Pellegrini AV, "Antibiotics and cement:what I need to know?", Hip Int, 30(1_suppl), pp.48~53 (2020)
88. Won-Sung Kim, "Percutaneous osteoplasty for painful bony lesions: a technical survey", The Korean Journal of Pain, 34(4), pp.375~393 (2021), 대한통증학회[DOI]
89. Ross JJ, "Septic arthritis of native joints", Infect Dis Clin North Am, 31, pp.203~218 (2017)
90. García-Arias M, "Septic arthritis", Best Pract Res Clin Rheumatol, 25, pp.407~421 (2011)
91. Horowitz DL, "Approach to septic arthritis", Am Fam Physician, 84, pp.653~660 (2011)
92. Long B, "Evaluation and management of septic arthritis and its mimics in the emergency department", West J Emerg Med, 20, pp.331~341 (2019)
93. Elsissy JG, "Bacterial septic arthritis of the adult native knee joint: a review", JBJS Rev, 8, pp.e0059~ (2020)
94. Stutz G, "Diagnosis and stage-related therapy of joint infections", Unfallchirurg, 104, pp.682~686 (2001)
95. Balato G, "Management of septic arthritis of the hip joint in adults. A systematic review of the literature", BMC Musculoskelet Disord, 22(Suppl 2), pp.1006~ (2021)
96. Jiang JJ, "Septic arthritis of the shoulder : a comparison of treatment methods", J Am Acad Orthop Surg, 25, pp.e175~e184 (2017)
97. Movassaghi K, "Septic arthritis of the native ankle", JBJS Rev, 7, pp.e6~ (2019)
98. Lener S, "Management of spinal infection : a review of the literature", Acta Neurochir (Wien), 160, pp.487~496 (2018)
99. Duarte RM, "Spinal infection : state of the art and management algorithm", Eur Spine J, 22, pp.2787~2799 (2013)
100. Gouliouris T, "Spondylodiscitis : update on diagnosis and management", J Antimicrob Chemother, 65(Suppl 3), pp.iii11~iii24 (2010)
101. Choi EJ, "Percutaneous endoscopic debridement and drainage with four different approach methods for the treatment of spinal infection", Pain Physician, 20, pp.E933~E940 (2017)
102. 이규열, "Comparison of Pyogenic Spondylitis and Tuberculous Spondylitis", Asian Spine Journal, 8(2), pp.216~223 (2014), 대한척추외과학회
103. Raff AB, "Cellulitis : a review", JAMA, 316, pp.325~337 (2016)
104. Sullivan T, "Diagnosis and management of cellulitis", Clin Med (Lond), 18, pp.160~163 (2018)
105. Rrapi R, "Cellulitis : a review of pathogenesis, diagnosis, and management", Med Clin North Am, 105, pp.723~735 (2021)
106. Stevens DL, "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America", Clin Infect Dis, 59, pp.e10~e52 (2014)
107. Nauclér P, "Impact of time to antibiotic therapy on clinical outcome in patients with bacterial infections in the emergency department : implications for antimicrobial stewardship", Clin Microbiol Infect, 27, pp.175~181 (2021)
108. 이미숙, "Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia", Infection and Chemotherapy, 50(2), pp.160~198 (2018), 대한감염학회
109. Eisen DP, "Longer than 2hours to antibiotics is associated with doubling of mortality in a multinational community-acquired bacterial meningitis cohort", Sci Rep, 12, pp.672~ (2022)
110. Nakatani S, "JCS 2017 guideline on prevention and treatment of infective endocarditis", Circ J, 83, pp.1767~1809 (2019)
111. Oshima T, "Empiric antibiotic therapy for severe sepsis and septic shock", Surg Infect (Larchmt), 17, pp.210~216 (2016)
112. Leekha S, "General principles of antimicrobial therapy", Mayo Clin Proc, 86, pp.156~167 (2011)
113. "Infection management guidelines empirical antibiotic therapy in adults" (2020)[URL]
114. "Empirical antimicrobial therapy prescribing guidance for adults. Version 6" (2018)[URL]
115. Beveridge TJ, "Use of the gram stain in microbiology", Biotech Histochem, 76, pp.111~118 (2001)
116. Popescu A, "The Gram stain after more than a century", Biotech Histochem, 71, pp.145~151 (1996)
117. Coico R, "Gram staining", Curr Protoc Microbiol (2005)
118. Sarkar P, "A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics", Medchemcomm, 8, pp.516~533 (2017)
119. Garnacho-Montero J, "Antibiotic de-escalation in the ICU: how is it best done?", Curr Opin Infect Dis, 28, pp.193~198 (2015)
120. De Waele JJ, "Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care : no simple answers to simple questions-a viewpoint of experts", Intensive Care Med, 46, pp.236~244 (2020)
121. Kowalska-Krochmal B, "The minimum inhibitory concentration of antibiotics : methods, interpretation, clinical relevance", Pathogens, 10, pp.165~ (2021)
122. Patel K, "A comprehensive overview of antibiotic selection and the factors affecting it", Cureus, 13, pp.e13925~ (2021)
123. Pankey GA, "Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections", Clin Infect Dis, 38, pp.864~870 (2004)
124. "Critically important antimicrobials for human medicine" (2019)[URL]
125. Bush K, "β-Lactams and β-lactamase inhibitors : an overview", Cold Spring Harb Perspect Med, 6, pp.a025247~ (2016)
126. Roberts JA, "Therapeutic drug monitoring of antimicrobials", Br J Clin Pharmacol, 73, pp.27~36 (2012)
127. Mabilat C, "Diagnostic and medical needs for therapeutic drug monitoring of antibiotics", Eur J Clin Microbiol Infect Dis, 39, pp.791~797 (2020)
128. Wong G, "How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?", BMC Infect Dis, 14, pp.288~ (2014)
129. "Therapeutic Drug Monitoring (TDM) protocol for adult: vancomycin and aminoglycosides" (2019)[URL]
130. Wang N, "Antibiotic combination therapy : a strategy to overcome bacterial resistance to aminoglycoside antibiotics", Front Pharmacol, 13, pp.839808~ (2022)
131. Abdul-Aziz MH, "Antimicrobial therapeutic drug monitoring in critically ill adult patients : a Position Paper", Intensive Care Med, 46, pp.1127~1153 (2020)
132. Shrayteh ZM, "Practice of switch from intravenous to oral antibiotics", Springerplus, 3, pp.717~ (2014)
133. Cyriac JM, "Switch over from intravenous to oral therapy : a concise overview", J Pharmacol Pharmacother, 5, pp.83~87 (2014)
134. Pletz MW, "Who benefits from antimicrobial combination therapy?", Lancet Infect Dis, 17, pp.677~678 (2017)
135. Tejaswini YS, "Practice of intravenous to oral conversion of antibiotics and its influence on length of stay at a tertiary care hospital : a prospective study", J Clin Diagn Res, 12, pp.FC01~FC04 (2018)
136. Ghafourian S, "Extended spectrum beta-lactamases : definition, classification and epidemiology", Curr Issues Mol Biol, 17, pp.11~21 (2015)
137. Rudresh SM, "Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance", Indian J Med Res, 133, pp.116~118 (2011)
138. Dhillon RH, "ESBLs: a clear and present danger?", Crit Care Res Pract, 2012, pp.625170~ (2012)
139. Bajpai T, "Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital", Avicenna J Med, 7, pp.12~16 (2017)
140. Saudagar PS, "Clavulanic acid : a review", Biotechnol Adv, 26, pp.335~351 (2008)
141. Akova M, "Sulbactam-containing beta-lactamase inhibitor combinations", Clin Microbiol Infect, 14(Suppl 1), pp.185~188 (2008)
142. López Montesinos I, "Ceftolozane-tazobactam : when, how and why using it?", Rev Esp Quimioter, 34(Suppl 1), pp.35~37 (2021)
143. Rodgers P, "Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections : Indian subset from RECLAIM", J Infect Dev Ctries, 16, pp.305~313 (2022)
144. Tanouchi Y, "Programming stress-induced altruistic death in engineered bacteria", Mol Syst Biol, 8, pp.626~ (2012)
145. Tängdén T, "Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria", Ups J Med Sci, 119, pp.149~153 (2014)
146. Marshall WF, "The cephalosporins", Mayo Clin Proc, 74, pp.187~195 (1999)
147. Barbaud A, "Intradermal tests with drugs : an approach to standardization", Front Med (Lausanne), 7, pp.156~ (2020)
148. 이소희, "The Current Practice of Skin Testing for Antibiotics in Korean Hospitals", The Korean Journal of Internal Medicine, 25(2), pp.207~212 (2010), 대한내과학회
149. Shenoy ES, "Evaluation and management of penicillin allergy : a review", JAMA, 321, pp.188~199 (2019)
150. Eun-Ji Kim, "Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it’s time to act now", The Korean Journal of Pain, 35(4), pp.361~382 (2022), 대한통증학회[DOI]
151. Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)

관련 논문AI추천